A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors

Clinical trial NCT06724263 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06724263
Sponsor: Tasly Biopharmaceuticals Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Platinum-resistant Epithelial Ovarian Cancer Triple Negative Breast Cancer (TNBC)Cervical Cancers Small Cell Lung Cancer Hepatocellular Carcinoma (HCC)Colorectal Cancer Non-Squamous Non-Small Cell Lung Cancer

Start date: 2024-12-01
Primary completion: 2026-08-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.